JAK
Gli inibitori della Janus chinasi (JAK) sono composti che prendono di mira la via di segnalazione JAK-STAT, coinvolta nella crescita cellulare, nella risposta immunitaria e nell'angiogenesi. Inibendo JAK, questi composti possono ridurre la segnalazione che porta alla formazione di nuovi vasi sanguigni nei tumori, inibendo così la crescita tumorale. Gli inibitori di JAK sono importanti nel trattamento del cancro e delle malattie infiammatorie. Presso CymitQuimica, offriamo una vasta gamma di inibitori di JAK di alta qualità per supportare la tua ricerca in oncologia, immunologia e angiogenesi.
Trovati 246 prodotti di "JAK"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Tyrphostin AG 490
CAS:Formula:C17H14N2O3Purezza:>98.0%(T)(HPLC)Colore e forma:White to Light yellow powder to crystalPeso molecolare:294.31Ilginatinib
CAS:Ilginatinib (NS-018) is a highly active and orally bioavailable inhibitor of JAK2.Formula:C21H20FN7Purezza:98.4% - 99.01%Colore e forma:SolidPeso molecolare:389.43Brepocitinib P-Tosylate
CAS:<p>Brepocitinib P-Tosylate (PF-06700841 P-Tosylate) is a potent dual inhibitor of Janus kinase 1 (JAK1) and TYK2 (IC50s of 17 nM and 23 nM, respectively).</p>Formula:C25H29F2N7O4SPurezza:99.82% - 99.97%Colore e forma:SolidPeso molecolare:561.6Delgocitinib
CAS:Delgocitinib is a potent JAK inhibitor (IC50: 2.8-58 nM), treats inflammatory diseases, and is the first topical drug for atopic dermatitis.Formula:C16H18N6OPurezza:99.95%Colore e forma:SolidPeso molecolare:310.35Ilginatinib maleate
CAS:<p>Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable inhibitor of JAK2.</p>Formula:C25H24FN7O4Purezza:99.74% - 99.82%Colore e forma:SolidPeso molecolare:505.5WDR5-IN-6
CAS:WDR5-IN-6 is a WDR5 inhibitor targeting the WBM locus.WDR5-IN-6 is highly synergistic with OICR-9429, a WDR5 inhibitor that targets the WIN locus.WDR5-IN-6Formula:C13H8Cl2N2O2SPurezza:99.69%Colore e forma:SoildPeso molecolare:327.19N-(3-Aminopropyl)cyclohexylamine
CAS:N-(3-Aminopropyl)cyclohexylamine inhibits spermine synthase; used in neuro disease research.Formula:C9H20N2Purezza:98.05% - 98.82%Colore e forma:Pale Yellow Clear LiquidPeso molecolare:156.2685JAK2 Inhibitor V
CAS:<p>JAK2 Inhibitor V (JAK2 Inhibitor V Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner.</p>Formula:C23H24N2OPurezza:98.36% - 99.15%Colore e forma:SolidPeso molecolare:344.45Gusacitinib
CAS:<p>Gusacitinib (ASN-002) (ASN-002) is spleen tyrosine kinase (SYK) and janus kinase (JAK) inhibitor (IC50: 5-46 nM).</p>Formula:C24H28N8O2Purezza:98.06% - 99.94%Colore e forma:SolidPeso molecolare:460.53Nimucitinib
CAS:Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.Formula:C25H26F2N6O2Purezza:99.58%Colore e forma:SoildPeso molecolare:480.51Ilginatinib hydrochloride
CAS:Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable inhibitor of JAK2.Formula:C21H21ClFN7Purezza:99.55%Colore e forma:SolidPeso molecolare:425.89Golidocitinib
CAS:Golidocitinib (AZD4205) is a selective JAK1 inhibitor (IC50: 73 nM) and weakly inhibits JAK2/JAK3 (IC50: >14.7, >30 μM).Formula:C25H31N9O2Purezza:98.87% - 99.88%Colore e forma:SolidPeso molecolare:489.57TAK-901
CAS:<p>TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others</p>Formula:C28H32N4O3SPurezza:99.02% - 99.59%Colore e forma:SolidPeso molecolare:504.64(E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide
CAS:Formula:C17H14N2O3Purezza:98%Colore e forma:SolidPeso molecolare:294.3047JAK1/STAT3-IN-1
JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).Formula:C30H33FN4O3SColore e forma:SolidPeso molecolare:548.67TYK2 activator-1
<p>TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.</p>Formula:C23H21FN4O2Colore e forma:SolidPeso molecolare:404.16485JAK/HDAC-IN-4
<p>JAK/HDAC-IN-4 (compound 11 i) is a dual inhibitor targeting both JAK2 and HDAC6, with IC50 values of 0.49 nM and 12 nM respectively. It inhibits cell proliferation and the production of nitric oxide. In a mouse model induced by Imiquimod, JAK/HDAC-IN-4 ameliorates psoriasiform skin lesions with low toxicity.</p>Formula:C30H32N8O5SColore e forma:SolidPeso molecolare:616.69JAK-STAT Compound Library
<p>A unique collection of 252 JAK/STAT signaling targeted compounds for high throughput and high content screening;</p>Colore e forma:Odour SolidJAK2-IN-6
CAS:JAK2-IN-6: A potent JAK2-specific inhibitor (IC50=22.86μg/mL), blocks JAK2 signaling, has anticancer properties, and is inactive against JAK1/3.Formula:C14H10ClN3OS2Purezza:99.64%Colore e forma:SolidPeso molecolare:335.83JAK-IN-15
CAS:<p>JAK-IN-15 is a JAK inhibitor. WO2016119700A1 (Compound 15).</p>Formula:C22H23FN4O3SColore e forma:SolidPeso molecolare:442.51Pumecitinib
CAS:<p>Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.</p>Formula:C17H20N8O2SPurezza:99.94%Colore e forma:SoildPeso molecolare:400.46SJ1008030
CAS:<p>SJ1008030, a JAK2 PROTAC, degrades JAK2; EC50: 5.4 nM, IC50: 32.09 nM in MHH-CALL-4 cells for leukemia research.</p>Formula:C42H43N13O7SColore e forma:SolidPeso molecolare:873.94PROTAC TYK2 degradation agent1
CAS:<p>PROTAC TYK2 Agent1 selectively degrades TYK2, with a 14 nM DC50, for autoimmune research.</p>Formula:C55H69N13O7SPurezza:98%Colore e forma:SolidPeso molecolare:1056.28SJ1008030 formic
SJ1008030 (compound 8) formic is a selective JAK2 degrader within the PROTAC class, demonstrating efficacy in inhibiting MHH-CALL-4 leukemia cell growth with anFormula:C43H45N13O9SPurezza:98%Colore e forma:SolidPeso molecolare:919.96Povorcitinib phosphate
CAS:<p>Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.</p>Formula:C23H25F5N7O5PPurezza:99.57%Colore e forma:SolidPeso molecolare:605.45JAK3-IN-15
<p>JAK3-IN-15 (compound 22) is a JAK3 inhibitor that reduces the secretion of p-JAK3 induced by LPS. It is utilized in research for rheumatoid arthritis.</p>Colore e forma:Odour SolidMR44397
<p>MR44397 is a ligand for WD40 repeat (WDR) 5 and is applicable in cancer research.</p>Formula:C23H26N4O2SColore e forma:SolidPeso molecolare:422.54JAK2-IN-10
CAS:<p>JAK2-IN-10 (compound 5) is a potent inhibitor of JAK2v617f, with an IC50 value of ≤10 nM.</p>Formula:C33H33D3FN9O2Colore e forma:SolidPeso molecolare:612.71FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Colore e forma:LiquidAdenosine receptor modulator 1
Adenosine receptor modulator 1 acts as an inducer of collagen VII (C7). It enhances the expression of COL7A1 mRNA in donor-derived keratinocytes and, in synergy with Gentamicin, increases the overall levels of C7.Formula:C25H28N6O3Colore e forma:SolidPeso molecolare:460.53Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)
CAS:<p>Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide derived from mouse JAK2, specifically composed of amino acids 475 to 491.</p>Formula:C88H138N20O34P2Purezza:98%Colore e forma:SolidPeso molecolare:2082.1TYD-68
<p>TYD-68 is a potent and selective CRBN-recruiting TYK2 PROTAC degrader, with a DC50 value of 0.42 nM. This compound effectively inhibits IL-12 and IFN-α-induced phosphorylation of STAT4 and STAT1, thereby blocking TYK2-dependent signaling pathways. TYD-68 is applicable in psoriasis research.</p>Colore e forma:Odour SolidSJ988497
CAS:SJ988497: PROTAC JAK2 degrader, inhibits CRLF2r cell growth, degrades GSPT1, combines Ruxolitinib, linker, Pomalidomide; researched for ALL.Formula:C36H36N10O5Colore e forma:SolidPeso molecolare:688.74JAK-IN-33
JAK-IN-33 (Compound 3 (R)) is a selective inhibitor of the Janus kinase (JAK) family [1].Purezza:98%Colore e forma:Odour SolidJI069
CAS:<p>JI069 (WAY-354189) is a potent STAT3 inhibitor that inhibits gp130 signaling by inducing dissociation between gp130 and JAK1.</p>Formula:C15H12Cl2N2O4SPurezza:98.01%Colore e forma:SolidPeso molecolare:387.24JAK-IN-29
JAK-IN-29 (Compound 3) is a potent inhibitor of Janus kinases (JAK) [1].Formula:C17H14ClN5O2Purezza:98%Colore e forma:SolidPeso molecolare:355.78HAT-SIL-TG-1&AT
HAT-SIL-TG-1&AT: a hypoxia-activated JAK inhibitor that curbs HEL cell growth & STAT3/5 phosphorylation in tumors.Formula:C60H69N17O11SColore e forma:SolidPeso molecolare:1236.36WDR5 ligand 2
CAS:<p>WDR5ligand 2 is a ligand for WDR5 and can be utilized in the synthesis of PROTAC WDR5degrader 1.</p>Formula:C29H31F3N4O4Colore e forma:SolidPeso molecolare:556.576Axltide
CAS:Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.Formula:C63H107N19O20S2Purezza:98%Colore e forma:SolidPeso molecolare:1514.77Deuruxolitinib
CAS:Deuruxolitinib functions as an inhibitor of JAK1/2.Formula:C17H18N6Colore e forma:SolidPeso molecolare:314.41JAK1/TYK2-IN-1
CAS:JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 ( IC 50 = 29 and 41 nM respectively).Formula:C18H20F3N7OColore e forma:SolidPeso molecolare:407.401Tyrosine Kinase Inhibitor Library
<p>A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase related</p>Colore e forma:Odour SolidSJ10542
CAS:SJ10542: potent JAK2/3-targeting PG-PROTAC; DC50s: JAK2 - 14 nM, JAK3 - 11 nM, JAK2-fusion ALL - 24 nM; CRBN recruiter.Formula:C41H46N12O5SColore e forma:SolidPeso molecolare:818.95Tyk2-IN-22
CAS:Tyk2-IN-22 (Compound A8) is a selective inhibitor of tyrosine kinase 2 (Tyk2), effectively inhibiting Tyk2, JAK1, and JAK3 with IC50 values of 9.7 nM, 148.6 nM, and 883.3 nM, respectively. Additionally, Tyk2-IN-22 suppresses downstream STAT5 phosphorylation.Formula:C16H16ClN5O2Colore e forma:SolidPeso molecolare:345.78JAK-2/3-IN-1
CAS:JAK-2/3-IN-1 inhibits JAK-2/3 isoforms with sub-250 nM Ki; from US patent US8163732B2.Formula:C20H12ClN3OColore e forma:SolidPeso molecolare:345.79Kinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Colore e forma:Odour SolidS-Ruxolitinib
CAS:<p>S-Ruxolitinib can be used in related research in the field of life sciences. Its product number is T3066 and CAS number is 1160597-27-2.</p>Formula:C17H18N6Purezza:98%Colore e forma:SolidPeso molecolare:306.37DBL-6-13
<p>DBL-6-13 is an inhibitor of WDR5, displaying moderate binding affinity with dissociation constants (Kd) of 6.8 μM and 9.1 μM as determined by microscale thermophoresis analysis and fluorescence polarization analysis, respectively.</p>Formula:C25H38N4O3Colore e forma:SolidPeso molecolare:442.59LH168
LH168 is a potent and selective probe for WDR5, with a SPR Kd value of 13 nM.Formula:C29H31F3N6O2SColore e forma:SolidPeso molecolare:584.66AS2553627
CAS:AS2553627 is a JAK inhibitor. AS2553627 prevents chronic rejection in rat cardiac allografts.Formula:C18H19N5OColore e forma:SolidPeso molecolare:321.38Ilunocitinib
CAS:Ilunocitinib is a non-selective and orally active Janus kinase (JAK) inhibitor for pruritus and atopic dermatitis caused by atopic dermatitis in dogs.Formula:C17H17N7O2SPurezza:99.88%Colore e forma:SolidPeso molecolare:383.43Atinvicitinib
CAS:Atinvicitinib, a selective JAK1 inhibitor, blocks cytokine signaling, modulating itch, allergy, and inflammatory responses, immune and therapeutic studies.Formula:C16H17FN6O3Purezza:99.36%Colore e forma:SolidPeso molecolare:360.35Ifidancitinib
CAS:Ifidancitinib (ATI-50002) is a JAK kinase 1/3 inhibitor used to study autoimmune diseases.Formula:C20H18FN5O3Purezza:98.05%Colore e forma:SolidPeso molecolare:395.39CHZ868
CAS:<p>CHZ868 is a type II JAK inhibitor with potential antitumor activity that reverses the persistence of type I JAK inhibitors and can be used to study leukemia.</p>Formula:C22H19F2N5O2Purezza:99.38%Colore e forma:SolidPeso molecolare:423.42WHI-P154
CAS:Formula:C16H14BrN3O3Purezza:>98.0%(HPLC)Colore e forma:White to Yellow to Orange powder to crystalPeso molecolare:376.21WHI-P180 Hydrochloride
CAS:Formula:C16H15N3O3·HClPurezza:>97.0%(T)(HPLC)Colore e forma:White to Light gray to Light yellow powder to crystalPeso molecolare:333.77Itacitinib adipate
CAS:Itacitinib adipate: oral JAK1 inhibitor, tested in phase II myelofibrosis trial.Formula:C32H33F4N9O5Colore e forma:SolidPeso molecolare:699.66DTP3
CAS:DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.Formula:C26H35N7O5Colore e forma:SolidPeso molecolare:525.6Fedratinib hydrochloride hydrate
CAS:Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.Formula:C27H40Cl2N6O4SPurezza:98.96% - 99.87%Colore e forma:SolidPeso molecolare:615.61Pacritinib
CAS:Pacritinib (SB1518) (SB1518) is an effective and specific inhibitor of JAK2 and FLT3 (IC50: 23/22 nM, in cell-free assays).Formula:C28H32N4O3Purezza:99.25% - 99.49%Colore e forma:SolidPeso molecolare:472.58Tofacitinib Citrate
CAS:<p>Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).</p>Formula:C22H28N6O8Purezza:99.19% - 99.75%Colore e forma:SolidPeso molecolare:504.49Abrocitinib
CAS:<p>Abrocitinib (PF-04965842) (PF-04965842) is a potent, specific and orally-active JAK1 inhibitor (IC50s: 29/803 nM for JAK1/2).</p>Formula:C14H21N5O2SPurezza:99.09% - 99.91%Colore e forma:SolidPeso molecolare:323.41AG490
CAS:AG490 inhibits EGFR (0.1 μM IC50), 135x > selective than ErbB2, blocks JAK2, spares Lyn, Lck, Syk, Btk, Src.Formula:C17H14N2O3Purezza:98.6% - 99.85%Colore e forma:Yellow SolidPeso molecolare:294.3Cucurbitacin I
CAS:<p>Cucurbitacin I (JSI-124), a natural compound, is a selective inhibitor of JAK2/STAT3 with anti-cancer activity.</p>Formula:C30H42O7Purezza:96.69% - 99.8%Colore e forma:SolidPeso molecolare:514.65SHR0302
CAS:<p>SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3,</p>Formula:C18H22N8O2SPurezza:99.11%Colore e forma:SolidPeso molecolare:414.48CEP-33779
CAS:CEP-33779 is a novel and selective inhibitor of JAK2 with an IC50 of 1.8±0.6 nM.Formula:C24H26N6O2SPurezza:98.24% - ≥95%Colore e forma:SolidPeso molecolare:462.57SAR-20347
CAS:SAR-20347 is an inhibitor of TYK2, JAK1/2/3 (IC50: 0.6/23/26/41 nM).Formula:C21H18ClFN4O4Purezza:98.99% - 99.77%Colore e forma:SolidPeso molecolare:444.84Gandotinib
CAS:LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM).Formula:C23H25ClFN7OPurezza:99.33% - 99.86%Colore e forma:SolidPeso molecolare:469.94Delgocitinib EtOH
CAS:Delgocitinib (LEO-124249/JTE052) is a selective JAK inhibitor used for reducing skin inflammation and treating chronic dermatitis.Formula:C18H24N6O2Colore e forma:SolidPeso molecolare:356.43BD750
CAS:BD750 is an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation(IC50 of 1.5 μM and 1.1 μM inFormula:C14H13N3OSPurezza:99.02%Colore e forma:SolidPeso molecolare:271.34AT9283
CAS:<p>AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).</p>Formula:C19H23N7O2Purezza:99.83% - 99.98%Colore e forma:SolidPeso molecolare:381.432,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
CAS:<p>2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide (GDC046), a potent lead analog, has good kinase selectivity and physicochemical properties.</p>Formula:C16H13Cl2N3O2Purezza:98.77%Colore e forma:SolidPeso molecolare:350.2Ruxolitinib phosphate
CAS:<p>Ruxolitinib phosphate (INCB18424 phosphate) is a JAK1/2 inhibitor with IC50 of 3.3 nM/2.8 nM. Cost-effective and quality-assured.</p>Formula:C17H21N6O4PPurezza:98% - >99.99%Colore e forma:SolidPeso molecolare:404.36GLPG0634 analog
CAS:GLPG0634 analog (GLPG0634 analogue) is a specific JAK1 inhibitor with IC50 of 10/28/810/116 nM for JAK1/2/3 and TYK2, respectively.Formula:C23H18N6O2Purezza:99.52% - >99.99%Colore e forma:SolidPeso molecolare:410.43Ritlecitinib
CAS:Ritlecitinib (PF-06651600) is an orally available, selective JAK3 inhibitor and does not affect the activity of JAK1/2.Cost-effective and quality-assured.Formula:C15H19N5OPurezza:98.82% - 99.92%Colore e forma:SolidPeso molecolare:285.34Pyridone 6
CAS:Pyridone 6, a selective JAK1/2/3 and Tyk2 inhibitor with IC50s: JAK1=15 nM, JAK2=1 nM, JAK3 (Ki=5 nM), Tyk2=1 nM; weakly binds other kinases (130 nM-10 μM).Formula:C18H16FN3OPurezza:97.1% - 98.74%Colore e forma:SolidPeso molecolare:309.34WHI-P97
CAS:WHI-P97 is a rationally designed potent inhibitor of JAK-3.Formula:C16H13Br2N3O3Purezza:99.93%Colore e forma:SolidPeso molecolare:455.1GDC-0214
CAS:GDC-0214 is an inhaled small-molecule JAK1 inhibitor and reduces fractional exhaled nitric oxide (Feno).Formula:C28H28ClF2N9O3Purezza:99.75%Colore e forma:SolidPeso molecolare:612.03Momelotinib HCl
CAS:<p>Momelotinib HCl is a JAK1/2 inhibitor, reducing anemia in myelofibrosis (MF) patients.</p>Formula:C23H24Cl2N6O2Colore e forma:SolidPeso molecolare:487.38FLLL32
CAS:<p>FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM).</p>Formula:C28H32O6Purezza:97% - 97.90%Colore e forma:SolidPeso molecolare:464.55Baricitinib
CAS:Baricitinib (INCB028050) is an orally JAK1 and JAK2 inhibitor. Baricitinib has anti-inflammatory and anti-tumor activity. Cost-effective and quality-assured.Formula:C16H17N7O2SPurezza:99% - >99.99%Colore e forma:SolidPeso molecolare:371.42AMG-47a
CAS:AMG-47a inhibits Lck, T cell growth, and degrades KRAS oncoprotein, affecting EGFP-KRASG12V but not EGFP.Formula:C29H28F3N5O2Purezza:98%Colore e forma:SolidPeso molecolare:535.56Decernotinib
CAS:Decernotinib (VRT-831509)(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.Formula:C18H19F3N6OPurezza:99.28% - >99.99%Colore e forma:SolidPeso molecolare:392.38WHI-P97 HCl
WHI-P97 HCl is a potent and selective JAK-3 inhibitor.Formula:C16H14Br2ClN3O3Purezza:99.49%Colore e forma:SolidPeso molecolare:491.56G5-7
CAS:G5-7 is an oral JAK2 inhibitor targeting EGFR/STAT3 phosphorylation with potential for glioma research.Formula:C22H19F2NO3Purezza:97.3%Colore e forma:SolidPeso molecolare:383.39AZ960
CAS:AZ960 is an effective ATP competitive JAK2 inhibitor (IC50/Ki: <3 nM and0.45 nM).Formula:C18H16F2N6Purezza:96.02% - 99.88%Colore e forma:SolidPeso molecolare:354.36RO495
CAS:<p>RO495 (CS-2667), a potent inhibitor of TYK2, inhibits TYK2 with IC50 of 1.5nM as tested in cell-based pharmacological assays</p>Formula:C17H14Cl2N6OPurezza:97.94%Colore e forma:SolidPeso molecolare:389.24NVP-BSK805 trihydrochloride
CAS:NVP-BSK805 trihydrochloride inhibits JAK2 (0.48 nM IC50); also affects JAK1, JAK3, TYK2.Formula:C27H31Cl3F2N6OColore e forma:SolidPeso molecolare:599.93Ruxolitinib (S enantiomer)
CAS:Ruxolitinib S enantiomer (INCB18424) is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor.Formula:C17H18N6Purezza:99.37% - 99.79%Colore e forma:SolidPeso molecolare:306.36WP1066
CAS:<p>WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3.</p>Formula:C17H14BrN3OPurezza:98.92% - 99.73%Colore e forma:SolidPeso molecolare:356.22RGB-286638 free base
CAS:RGB-286638 free base inhibits CDKs (1-5 nM), weaker on CDK7/6.Formula:C29H35N7O4Purezza:98% - 99.91%Colore e forma:SolidPeso molecolare:545.63(E/Z)-Zotiraciclib
CAS:(E/Z)-Zotiraciclib ((E/Z)-TG02) inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively.Formula:C23H24N4OPurezza:97.75% - 99.92%Colore e forma:SolidPeso molecolare:372.46Fedratinib
CAS:Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.Formula:C27H36N6O3SPurezza:97.31% - 99.96%Colore e forma:SolidPeso molecolare:524.68Deucravacitinib
CAS:Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor.Cost-effective and quality-assured.Formula:C20H19D3N8O3Purezza:98.52% - >99.99%Colore e forma:SolidPeso molecolare:425.46TG101209
CAS:<p>TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.</p>Formula:C26H35N7O2SPurezza:99% - >99.99%Colore e forma:SolidPeso molecolare:509.67XL019
CAS:XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1.Formula:C25H28N6O2Purezza:99.19%Colore e forma:SolidPeso molecolare:444.53Baricitinib phosphate
CAS:Baricitinib phosphate (INCB028050) is a selective orally bioavailable JAK1/JAK2 inhibitor.Formula:C16H20N7O6PSPurezza:99.4% - 99.91%Colore e forma:SolidPeso molecolare:469.41FM-381
CAS:<p>FM381, a JAK3 inhibitor with 127 pM IC50, is 410-3600x more selective over JAK1/2/TYK2.</p>Formula:C24H24N6O2Purezza:98.44%Colore e forma:SolidPeso molecolare:428.49
